Market Research Blog

According to the latest report published by Future Market Insights (FMI), sales of global dialyzer reprocessing machines and concentrates market were valued at US$ 967.4 Mn in 2018 and are expected to tread on an ever-increasing trajectory through 2028.

Dialysis continues to be highly preferred for effective treatment of chronic kidney diseases (CKD) among the geriatric population, thereby generating substantial demand for re-usable dialysis equipment. This, in turn, is foreseen to create revenue-generating opportunities for the companies operating in the dialyzer reprocessing machines and concentrates market.

North America Continues to Mark the most Significant Position in Market

According to the report, rising instances of renal disorders, such as end stage renal disease (ESRD) and chronic kidney disease (CKD), are among the key factors spurring growth of dialyzer reprocessing machines and concentrates market. Dialysis, being the most accessible treatment for kidney diseases, will thus continue to add to the overall importance of re-usable dialysis equipment. This, in turn, will create favourable grounds for adoption of global dialyzer reprocessing machines and concentrates market.

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-9272

In 2015, it was estimated by the National Kidney Foundation in the US that approximately 468,000 ESRD patients are reported to be on dialysis in the US alone. North America will thus continue to be a prominent region in the global dialyzer reprocessing machines and concentrates market, followed by South Asia. In 2018, North America accounted for a revenue share of around 24% in dialyzer reprocessing machines and concentrates market, backed by a robust healthcare infrastructure.

India, Sri Lanka, and, Thailand on the other side are likely to emerge as potential countries brimming with prime opportunities for the companies operating in the dialyzer reprocessing machines and concentrates market.

According to the report, introduction of technologically advanced medical equipment all-aligned with the evolving healthcare models is further expected to boost the growth of dialyzer reprocessing machines and concentrates market. dialyzer reprocessing machines and concentrates enable automated cleaning and reprocessing of the dialysis units, unlike the traditional re-usable systems that required manual handling. As per the research study, dialyzer reprocessing machines provide immense scope for direct handling of the dialysis systems using automated digital reprocessors, which is an added advantage boosting popularity of dialyzer reprocessing machines and concentrates over the conventional systems.

Dialyzer Reprocessing Machines and Concentrates Market: Significant Unmet Need for Dialyzer Re-use in Emerging Countries to Spur Growth: Global Industry Analysis 2013 – 2017 and Opportunity Assessment 2018 – 2028: https://www.futuremarketinsights.com/reports/dialyzer-reprocessing-machines-and-concentrates-market

The report opines that the end-users will continue to showcase marked preferences for hemodialysis concentrates among all other product types in the dialyzer reprocessing machines and concentrates market space. Hospitals are anticipated to lead in terms of adoption of dialyzer reprocessing machines and concentrates, followed by dialysis centres.

Key Manufacturers Emphasize Stronger Distribution Network for Better Regional Foothold

The dialyzer reprocessing machines and concentrates market report profiles few of the key companies operating in the global market space with robust product portfolios. Some of these key players in the dialyzer reprocessing machines and concentrates market include CURA Healthcare, MEDIVATORS Inc., Fresenius Medical Care, Baxter, Anjue Medical Equipment Co., Ltd., B. Braun Melsungen AG, Nipro Corporation, Cantel Medical, AIN MEDICARE SDN BHD and Rockwell Medical.

Buy Full Report of Dialyzer Reprocessing Machines and Concentrates Market Now: https://www.futuremarketinsights.com/checkout/9272

A majority of the regional players in the dialyzer reprocessing machines and concentrates market are focused on increasing their product reach and connectivity with the regional distributors of dialyzer reprocessing machines and concentrates. The dialyzer reprocessing machines and concentrates manufacturers are focused to strengthen their foothold in potential dialyzer reprocessing machines and concentrates markets such as India, China, Thailand, Bangladesh, and Argentina by expanding their sales and distribution channels across these countries.

Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/askus/rep-gb-9272

More from FMI’s Healthcare, Pharmaceuticals and Medical devices Market Intelligence:

• Bioimpedance Devices Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 to 2028
• Sports Drug Testing Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2028
• Focused Ultrasound System Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2028

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact:
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com/

Exceeding the revenue of US$ 1 billion in 2018, the global sales of gastroesophageal disease devices will witness a steady over 4% CAGR during 2018-2028. As indicated in a new intelligence outlook of Future Market Insights (FMI), esphagoscopes and gastroscopes will continue to account for most of the sales. Adoption of gastroesophageal reflux disease devices will remain maximum for diagnostic procedures, followed by fundoplication procedures.

More Patients Continue to Prefer GERD Devices over Lifestyle Modifications & PPIs

Besides the rapid expansion of geriatric population and elevating prevalence rate of obesity-driven gastroesophageal reflux diseases, FMI in a new study states that the frequent intake of asthma medications is also a strong impact factor associated with the growth of gastroesophageal reflux disease devices market.

Although industry experts recommend lifestyle modifications as the most suitable remedy for gastroesophageal diseases, the growing demand for surgeries for obesity will continue to drive sales of gastroesophageal disease devices in coming years.

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-1741

Although industry experts recommend lifestyle modifications as the most suitable remedy for gastroesophageal diseases, the growing demand for surgeries for obesity will continue to drive sales of gastroesophageal disease devices in coming years.

The second line of treatment for gastroesophageal reflux disease includes proton pump inhibitors (PPI) therapy, which can reduce the usage of gastroesophageal reflux disease devices. Proton pump inhibitors are the drugs that regulate acid production within stomach, and thereby restrict gastroesophageal reflux.

However, the proven side effects and functional failure of proton pump inhibitors in the long run will continue to benefit the demand for surgical treatment of gastroesophageal reflux disease, favoring the overall sales of gastroesophageal reflux disease devices such as PH monitoring system and manometry system.

For More Information On This Report, Please Visit @ https://www.futuremarketinsights.com/checkout/1741

Diagnostic Centers & Private Clinics to Employ More GERD Devices

While a majority of adoption of gastroesophageal reflux disease devices prevails in hospitals, the constantly increasing number of establishments in the ambulatory surgical center and diagnostic center segments is likely to translate into a higher rate of adoption of gastroesophageal reflux disease devices within the latter two.

With the number of diagnostic centers and private practice clinics on the constant rise, it is more likely that the demand for gastroesophageal reflux disease devices will observe steady growth over the years to come. Towards the end of forecast period, global market value share of clinics and diagnostic centers will be more than 35%, as suggested by FMI’s analysis of the gastroesophageal reflux disease devices market.

Preview Analysis Global Gastroesophageal Reflux Diseases Devices Market: by Product Type – Diagnostic Devices, Manometry System, PH Monitoring System, Esophagoscopes and Gastroscopes, Treatment Devices, Ultrasonic Surgical Endostapler, Fundoplication Devices, Sphincter Augmentation Devices, Radiofrequency Ablation Devices; by Procedure Type – Diagnostic Procedures, Fundoplication Procedures, Radiofrequency Thermal Ablation, Magnetic Sphincter Augmentation: https://www.futuremarketinsights.com/reports/gastroesophageal-reflux-diseases-devices-market

Key GERD Device Manufacturers Eyeing New Product Launches

The report tracks some of the key companies operating in the Gastroesophageal Reflux Disease Devices market, such as Olympus Corporation, Pentax Medical, Medtronic Plc., Diversatek Inc. The report also tracks the key manufacturers operating in gastroesophageal reflux disease treatment devices, such as EndoGastric Solutions, Medigus Ltd., Torax Medical, Inc. and Mederi RF, Inc.

A majority of key manufacturers of gastroesophageal reflux disease devices are emphasizing new product launches. Innovation of new and advanced products is in turn shaping the growth of gastroesophageal reflux disease devices market.

According to the report findings,

• Olympus Corporation and Pentax Medical hold the maximum company share in the gastroesophageal reflux disease devices market.
• Olympus Corporation recently launched an advanced version of esophagoscope and gastroscope.
• Plc. and Diversatek, Inc. are the key players of diagnostic devices for gastroesophageal reflux disease, contributing a significant share in overall gastroesophageal reflux disease devices market.
• EsophyX Z is the new and advanced version of EsophyX gastroesophageal reflux disease device, used for the transoral incisionless fundoplication process.

Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/askus/rep-gb-1741

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact:
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com/

Increasing acceptance of therapeutic nuclear medicines (or radiopharmaceuticals) among industry experts will remain a prominent factor encouraging their adoption. Though associated with a negligible risk factor, radiopharmaceuticals are likely to witness growing recommendation owing to no proven significant adverse effects.

In the backdrop of the growing criticality of a more reliable, safer, and lesser harmful line of treatment for cancers, therapeutic nuclear medicines are being increasingly perceived as the potential treatment for cancer patients. Moreover, consistently surging instances of bone metastases further supports adoption growth, in the therapeutic nuclear medicines market.

Just-under 10% Annual Growth Projected for Radiopharmaceuticals Adoption

A recent market research intelligence by Future Market Insights focuses on the deep-dive evaluation of global therapeutic nuclear medicines landscape, emphasizing the analysis of the most influential factors responsible for surging acceptance of radiopharmaceuticals in treating a range of cancers and a few other chronic conditions.

The study projects robust progress for the global radiopharmaceuticals market in coming years, reportedly driven by remarkable adoption in the treatment of prostate cancer. In 2019, the global demand for therapeutic nuclear medicines is expected to grow at a 9.7% annual rate, and maximum adoption is estimated by cancer research institutes at a global level.

• North America, jointly with Western Europe, represents more than 65% share of the total market value.
• Outpacing developed regional markets, the radiopharmaceuticals market in China and emerging economies across Asia Pacific, Latin America, and Middle East & Africa are slated for higher year on year revenue growth of over 12% in 2019 and ahead.
• China is reportedly the most lucrative market for penetration of therapeutic nuclear medicines, which is attributed to an expanding cancer patient pool in the country and a consistently surging rate of radiopharmaceuticals recommendation.

Request For Sample Copy @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2930

Top Three Companies Account for More than 87% Market Value Share

A highly consolidated marketplace, global therapeutic nuclear medicines landscape is dominated by Bayer AG that currently accounts for just-under 80% revenue share in market. The top three players include GE Healthcare and Novartis AG other than Bayer, which collectively cover over 87% of the total valuation of radiopharmaceuticals market. While exceptional sales and success rate of Xofigo have been prominently retaining Bayer’s top position in the global market, strategic acquisitions are identified to be the key strategy behind Novartis’ success at a global level.

Thorough assessment of the competitive landscape of global therapeutic medicines market reveals a few prominent developmental strategies adopted by a majority of key companies operating in radiopharmaceuticals landscape –

• Investments in R&D of targeted cancer therapeutics
• Stronger supply chain and more streamlined distribution network
• Improved flagship product sales
• Strategic collaborations with pharma/biopharmaceutical companies
• Contractual relationships with domestic/regional stakeholders
• Strategic deals with internationally recognized cancer research institutes

Therapeutic Nuclear Medicines Market

Over 20% Growth Forecast for Erbium-169

Radium-223 has been the highest recommended type of radionucleotide in radiopharmaceuticals market. While it currently accounts for a whopping 78% share in the global market revenue, it is more likely that Erbium-169 that has been witnessing higher traction in recent past would witness relatively higher revenue growth in coming years. The report forecasts over 20% year on year revenue growth for Erbium-169 in 2019.

Exceptional Growth Projections for Thyroid & Brain Cancer

While over half the global market value is accounted by the adoption of therapeutic nuclear medicines for treatment of prostate cancer, bone metastases also accounts for sizable revenue generation in the market. Brain tumor and thyroid cancer are likely to emerge highly lucrative targets for manufacturers of therapeutic nuclear medicines, according to the report.

Get TOC @ https://www.futuremarketinsights.com/reports/therapeutic-nuclear-medicines-market/table-of-content

Table of Content

1. Executive Summary

1.1. Market Overview

1.2. Market Analysis

1.3. FMI Analysis and Recommendations

1.4. Wheel of Fortune

1. Market Introduction

2.1. Market Taxonomy

2.2. Market Definition

2.3. Exclusion and Inclusion

1. Global Economic Outlook

3.1. Gross Domestic Product by Country, 2006 – 2021

3.2. Global Pharmaceutical Market Overview

1. Market Opportunity Analysis

4.1. Macro-Economic Factors

4.2. Opportunity Analysis

1. Market Dynamics

5.1. Drivers

5.1.1. Supply Side Drivers

5.1.2. Demand Side Drivers

5.2. Restraints

5.3. Trends

1. Key Inclusion

6.1. Parent Market Analysis

6.2. Key Regulation

6.3. Reimbursement Scenario

6.4. Pipeline Assessment

6.5. Disease Epidemiology

According to a recent study published by National Center for Biotechnology Information (NCBI) in May 2020, the overall prevalence of onychomycosis was approximately 5.5% in the general population.

The prevalence of onychomycosis has been increasing over the past few years due to unhealthy lifestyle and negligence of nail care. Future Market Insights (FMI) presents a positive outlook for the onychomycosis treatment market, forecasting it to exhibit 6.1% Y-o-Y growth in 2021.

Toenail onychomycosis are more common and requires longer duration of treatment, which can also extend to a year. Sometimes complete cure, defined as clinical cure, is unattainable, which may lead to indefinite treatment duration and consequently drive the onychomycosis treatment market. The risk of onychomycosis is 1.9 to 2.8 times higher in people with diabetes, compared with the general population. This is leading to rising revenue accumulation of drug manufacturers targeting the onychomycosis treatment market.

To remain ‘ahead’ of your competitors, request for a sample

The increasing risk factors such as nail injury or nail surgery, diabetes, weakened immune system, blood circulation disorders, athlete’s foot or ringworm, and others are driving the onychomycosis treatment market. The growing risk of occupational hazards such as agriculture, waste disposal, and others is also propelling the growth of the onychomycosis treatment market.

Diabetes and related conditions contributing to poor peripheral circulation are the major drivers of the market. Onychomycosis may represent an important forecast for the development of diabetic foot syndrome and foot ulcers. Patients who are immunosuppressed, such as those undergoing cancer therapy and those with HIV infection also are predisposed to fungal nail infection.

Coronavirus pandemic has changed the public medical care needs and spending however this is viewed as transient effect on the onychomycosis treatment market. The increasing COVID-19 patient pool attracted spotlight to the treatment of these patients on emergency basis, consequently reducing the patient visits to the medical clinics for onychomycosis treatment.

Decreasing visits demonstrate lesser treatment reception that resulted in temporary contraction of sales. Nonetheless, demand is likely to recover in the coming years with drugs emerging as more preferred type of treatment. The drugs segment is expected to account for nearly 75% of revenue generated in the market.

Key Takeaways from Onychomycosis Treatment Market Study

• High spending power supports growth in the U.S., sealing its dominance in North America. The U.S. is expected to account for over 84% of sales registered in the region
• The demand from the U.K. will continue rising, enabling year-on-year growth at above 7%
• Germany and France too will continue exhibiting high demand
• Within East Asia, Japan holds dominance, yet demand from China is likely to rise at a higher pace

“Market players are likely to focus on merger and acquisition to expand their footprint worldwide. They are also expected to focus on capitalizing on opportunities across emerging economies to gain competitive advantage,” said an FMI analyst.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-1279

Geriatric Population More Susceptible Onychomycosis

According to the World Health Organization (WHO), age is the key risk factor for the development of onychomycosis and the risk for onychomycosis increases with age, particularly for persons aged >50 years. Approximately, about 80-85% of onychomycosis occurs in patients aged greater than 50 years, globally. The rise in elderly population will therefore present lucrative growth opportunities to onychomycosis treatment market.

Who is Winning?

Key players in the onychomycosis treatment market are keenly focusing on strategic activities such as acquisitions, collaborations and mergers in order to create a strong position.

For Instance, In September 2018, Almirall S.A. acquired of portfolio of five products comprising of Allergan’s Medical dermatology unit in the U.S. to further enhance the company’s dermatology portfolio.

In 2017, Ziarco Group ltd. was acquired by Novartis acquired. Ziarco Group ltd. a privately held company in the U.K. The company focuses on the development of novel treatments in the field of dermatology.

Key Players

• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Medimetriks Pharmaceuticals, Inc.
• Galderma
• Johnson & Johnson
• Novartis AG
• Moberg Pharma AB
• Cardinal Health, Inc.
• Pfizer Inc.
• Almirall, S.A.
• Bayer AG
• Viatris Inc.
• GlaxoSmithKline plc
• Cipla Ltd.
• Dr. Reddy’s Laboratories Ltd

Onychomycosis Treatment Market by Category

Treatment Type

• Drugs
  • Oral
    • Rx
    • OTC
  • Topical
    • Rx
    • OTC
• Lasers
  • C02 Ablative Lasers
  • Nd:YAG Lasers
  • Dual-wavelength near-infrared Lasers
• Photodynamic Therapy

Disease Indication

• Distal Subungual Onychomycosis
• White Superficial Onychomycosis
• Proximal Subungual Onychomycosis
• Candidal Onychomycosis
• Total Dystrophic Onychomycosis

Age Group

• 0-18 Years
• 18-39 Years
• 40-64 Years
• 65 Years & Above

Gender

• Male
• Female

Distribution Channel

• Institutional Sales
  • Hospitals
  • Dermatology Clinics
• Retail Sales
  • Retail Pharmacies
  • Drug Stores
  • Mail Order Pharmacies & Online Sales

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-1279

Region

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa (MEA)